Macleods Recalls 3,744 Blood Pressure Pill Bottles Nationwide
By @sharedot · · 6 pages
- Crypto
- Health
- FDA Recall
- Blood Pressure Medication
Macleods Pharma USA recalled 3,744 blood pressure pill bottles nationwide after tablets failed FDA dissolution testing, a Class II action.
What was recalled and why
New Jersey-based Macleods Pharma USA is recalling certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets, a combination prescription drug used to treat high blood pressure, after the medication failed to meet federal quality standards, according to the U.S. Food and Drug Administration.
The recall covers 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B — 3,744 bottles in all — with both lots expiring May 31, 2027. The FDA listed the reason as "failed dissolution specifications," meaning the pills did not dissolve as required during testing.
Consumers can check their prescription bottles for the lot number and the National Drug Code: the recalled 30-count bottles carry NDC 33342-246-07, while the 90-count bottles carry NDC 33342-246-10.
Why the Class II rating matters
The FDA classified the action as a Class II recall on October 26, 2026, after Macleods initiated it on October 7.
That rating means use of the affected medication "may cause temporary or medically reversible adverse health consequences," but the agency considers the likelihood of serious health consequences remote. The recall remains ongoing and affects products distributed nationwide.
For patients, the practical question is what to do with a bottle that matches the lot numbers: Fox Business notes the recall affects drugs dispensed across the country, and the FDA's notice is the reference point pharmacists will use.
Patients who find a matching bottle should contact their doctor or pharmacist rather than simply discarding a blood pressure prescription, since uncontrolled hypertension carries its own risks.
A pattern of dissolution failures
The surprise is how quickly this is becoming a pattern for blood pressure medications.
Fox Business reports the Macleods recall comes weeks after India-based Inventia Healthcare Ltd. recalled 13,567 bottles of 25-milligram chlorthalidone tablets in September after that medication also failed dissolution testing; chlorthalidone is used to treat high blood pressure and fluid retention, according to Mayo Clinic.
WVTM 13 adds more timeline detail, reporting that Inventia first recalled certain lots of chlorthalidone tablets in June, then initiated a separate recall involving an additional lot on September 3, 2026, which the FDA classified as Class II on September 17, 2026.
Separately, PhillyBurbs/USA TODAY reports Viatris recalled 21,620 bottles of its telmisartan and amlodipine tablets because they may contain more telmisartan than specified — a Class III recall the company initiated October 1.
What patients should do next
The immediate takeaway is a medicine-cabinet check: match the drug name, lot number and NDC against the FDA notice before continuing to take the pills.
Viatris' recall notice, as reported by PhillyBurbs, carries a warning worth repeating even though it concerns a different drug: patients should not stop taking blood pressure medication abruptly, because potential withdrawal effects may be more harmful than the defect itself, and anyone with questions should reach out to their doctor or pharmacist.